Boston Scientific will purchase Plymouth-based privately held company, Atritech. As per the deal, Boston Scientific will make an upfront payment of $100 million and additional potential payments of $275 million upon completing specified regulatory and revenue-based milestones through 2015.

The purchase price of the heart device maker assumes no cash and no debt on its balance sheet at closing. The transaction, which is expected to be completed in the first quarter of 2011, will cut about one cent to two cents a share from Boston’s earnings in 2011, 2012 and 2013, while adding to earnings starting in 2014.

Click here for the release from PR Newswire.